Investment Analysts’ Weekly Ratings Changes for Rocket Pharmaceuticals (RCKT)

Several analysts have recently updated their ratings and price targets for Rocket Pharmaceuticals (NASDAQ: RCKT):

• 3/8/2026 – Rocket Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/2/2026 – Rocket Pharmaceuticals had its price target raised by The Goldman Sachs Group, Inc. to $3.00. They now have a “sell” rating on the stock.
• 2/28/2026 – Rocket Pharmaceuticals was upgraded by Wall Street Zen from “strong sell” to “hold”.
• 2/27/2026 – Rocket Pharmaceuticals had its price target raised by Cantor Fitzgerald from $8.00 to $10.00. They now have an “overweight” rating on the stock.
• 2/26/2026 – Rocket Pharmaceuticals was upgraded by Lifesci Capital to “strong-buy”.

Insider Activity

In related news, General Counsel Martin Wilson sold 12,253 shares of the company’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,557.43. Following the transaction, the general counsel owned 683,376 shares in the company, valued at $2,261,974.56. This represents a 1.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Gaurav Shah sold 12,279 shares of the stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $3.31, for a total transaction of $40,643.49. Following the sale, the chief executive officer directly owned 1,052,045 shares in the company, valued at approximately $3,482,268.95. This represents a 1.15% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 29,415 shares of company stock worth $97,398. 24.76% of the stock is owned by corporate insiders.

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.